Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;32(2):176-81.
doi: 10.1007/s12288-015-0559-5. Epub 2015 May 30.

Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation

Shreeniwas Raut  1 , Sandip Shah  1 , Kamalesh Shah  1 , Kinnari Patel  1 , Shailesh Talati  1 , Sonia Parikh  1 , Asha Anand  1 , Harsha Panchal  1 , Apurva Patel  1 , Akhil Jain  1
Affiliations

Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation

Shreeniwas Raut et al. Indian J Hematol Blood Transfus. 2016 Jun.

Abstract

We report analysis of all consecutive Hodgkins disease patients undergoing autologous hematopoietic stem cell transplant from September 1999 to December 2014. Out of total 38 patients 26 were males and 12 were females. 32 were adults and 6 were pediatric (<18 years). None were elderly. Median age was 28 years (9-61). All received BEAM protocol as conditioning regimen. Median engraftment time for granulocytes was 12 and 14 days for platelets. Thirty three (86.84 %) patients achieved complete remission out of which 8 (24.24 %) had further relapse. Transplant related mortality occurred in 4 (10 %) patients. Finally 26 (78.78 %) patients were disease free at median follow up of 60 months and median disease free survival (DFS) was 35 months. DFS was 66.66 and 65 %, respectively on 3 and 5 years. While overall survival was 70.83 and 70 % on 3 and 5 years, respectively.

Keywords: Autologus; Hodgkins; Stem cell; Transplantation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival (OS) and disease free survival (DFS) of post HSCT Hodgkins disease patients versus time
Fig. 2
Fig. 2
Progression free survival of chemosensitive disease and that of chemoresistant disease
See this image and copyright information in PMC

References

    1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased chemotherapy compared with COPP–ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–2395. doi: 10.1056/NEJMoa022473. - DOI - PubMed
    1. Longo D, Duffey P, Young R, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–218. - PubMed
    1. Ljungman P, Bregni M, Brune M, et al. Allogenic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transpl. 2010;45:219–234. doi: 10.1038/bmt.2009.141. - DOI - PubMed
    1. Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):653–662. doi: 10.1056/NEJMra1003733. - DOI - PubMed
    1. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2009;2009:497–506. doi: 10.1182/asheducation-2009.1.497. - DOI - PubMed